CVA Family Office’s AstraZeneca AZN Stock Holding History

CVA Family Office’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.31K	Hold	28	–	–	﹤0.01%	1256
2026 Q1	$5.52K	Buy	+28	New	+$5.4K	﹤0.01%	1199
2024 Q3	–	Sell	-504	Closed	-$78.5K	–	1277
2024 Q2	$78.5K	Hold	504	–	–	0.01%	399
2024 Q1	$68.2K	Sell	504 -106	-17%	-$14K	0.01%	428
2023 Q4	$82.1K	Buy	+610	New	+$79.3K	0.02%	367
2023 Q3	–	Sell	-610	Closed	-$87.2K	–	292
2023 Q2	$87.2K	Hold	610	–	–	0.02%	329
2023 Q1	$84.6K	Sell	610 -85	-12%	-$11.4K	0.02%	338
2022 Q4	$94.2K	Buy	695 +85	+14%	+$10.7K	0.02%	298
2022 Q3	$67K	Hold	610	–	–	0.02%	301
2022 Q2	$81K	Hold	610	–	–	0.02%	274
2022 Q1	$81K	Hold	610	–	–	0.02%	296
2021 Q4	$71K	Buy	+610	New	+$71.8K	0.02%	300
2021 Q3	–	Sell	-504	Closed	-$60K	–	409
2021 Q2	$60K	Buy	+504	New	+$55.3K	0.02%	336

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CVA Family Office's AZN Position: Q2 2026 in Review

CVA Family Office held its AstraZeneca (AZN) position steady in Q2 2026 at 28 shares worth $5.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

CVA Family Office first reported a position in AZN in Q2 2021 and has held it in 13 quarters since. The position peaked at $94.2K in Q4 2022. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

CVA Family Office held 28 shares of AstraZeneca worth $5.31K as of Q2 2026.
CVA Family Office left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1256 holding.
CVA Family Office first reported a position in AstraZeneca in Q2 2021 and has held it in 13 quarters since.
CVA Family Office's AstraZeneca position peaked at $94.2K in Q4 2022.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.